Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 7/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7068401 | 0.91 | ZDHHC2 (0.41) | ZDHHC2FAAH | |
| SCHEMBL1885123 | 0.87 | ZDHHC2 (0.55) | ZDHHC2FAAHLTA4HTSHRTDP1 | |
| SCHEMBL7070774 | 0.85 | MAPT (0.40) | ZDHHC2TDP1L3MBTL1 | |
| SCHEMBL7070772 | 0.85 | MAPT (0.40) | ZDHHC2TDP1L3MBTL1 | |
| SCHEMBL31619365 | 0.81 | FAAH (0.45) | ZDHHC2FAAHLTA4HTSHRTDP1 | |
| SCHEMBL7071829 | 0.77 | HTR1A (0.41) | ZDHHC2TDP1L3MBTL1 | |
| SCHEMBL7071830 | 0.77 | HTR1A (0.41) | ZDHHC2TDP1L3MBTL1 | |
| SCHEMBL9323400 | 0.75 | TSHR (0.54) | FAAHLTA4HTSHRTDP1L3MBTL1 | |
| SCHEMBL1790417 | 0.75 | ATM (0.42) | TSHR | |
| SCHEMBL7067820 | 0.75 | ATM (0.42) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6570015-B2 | Reacting alpha-keto ester with an isothiourea | UBE INDUSTRIES, LTD. (JP) | 2003-05-27 | — | — | US | claimed |
| US-20030055252-A1 | Process for producing 2-substituted thiopyrimidine-4-carboxylate | UBE INDUSTRIES, LTD. (JP) | 2003-03-20 | — | — | US | claimed |
| US-6570015-B2 | Reacting alpha-keto ester with an isothiourea | UBE INDUSTRIES, LTD. (JP) | 2003-05-27 | — | — | US | disclosed |
| US-20030055252-A1 | Process for producing 2-substituted thiopyrimidine-4-carboxylate | UBE INDUSTRIES, LTD. (JP) | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055252-A1 | Process for producing 2-substituted thiopyrimidine-4-carboxylate | DHFR, TYMS, DPYD | ZDHHC2 426/4885FAAH 3029/4885LTA4H 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.